PedAM

Pediatric Disease Annotations & Medicines


	meningitis, bacterial

Disease ID	1632
Disease	meningitis, bacterial
Synonym	bact meningitides bact meningitis bacterial meningitides bacterial meningitis bacterial meningitis (disorder) bacterial meningitis nos bacterial meningitis nos (disorder) bacterial meningitis, nos bm - bacterial meningitis meningitides bact meningitides, bacterial meningitis bact meningitis due to unspecified bacterium meningitis, bacterial [disease/finding] meningitis, bacterial nos
DOID	DOID:9470
MeSH	D016920
SNOMED-CT	SNOMEDCT_US_2016_09_01:95883001
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:43) C0025289 \| meningitis \| 7 C0038539 \| subdural empyema \| 3 C0032285 \| pneumoniae \| 3 C0025297 \| viral meningitis \| 2 C0004623 \| bacterial infection \| 2 C0029882 \| otitis media \| 2 C0023890 \| liver cirrhosis \| 2 C0014118 \| endocarditis \| 2 C0038463 \| strongyloidiasis \| 2 C0007785 \| cerebral infarction \| 2 C0018784 \| sensorineural hearing loss \| 2 C0007785 \| cerebral infarct \| 2 C0020255 \| hydrocephalus \| 2 C0014236 \| endophthalmitis \| 1 C0271429 \| acute otitis media \| 1 C0025294 \| meningococcal meningitis \| 1 C0023524 \| progressive multifocal leucoencephalopathy \| 1 C0021400 \| influenzae \| 1 C0008049 \| chickenpox \| 1 C0022116 \| ischemia \| 1 C0014070 \| encephalomyelitis \| 1 C0019045 \| haemoglobinopathy \| 1 C0041318 \| tuberculous meningitis \| 1 C0024530 \| malaria \| 1 C0007785 \| cerebral infarctions \| 1 C0267917 \| acute cholangitis \| 1 C0026764 \| multiple myeloma \| 1 C0008311 \| cholangitis \| 1 C0023860 \| listeriosis \| 1 C0025303 \| meningococcal disease \| 1 C0014059 \| acute disseminated encephalomyelitis \| 1 C0276430 \| enteroviral meningitis \| 1 C0037198 \| sinus thrombosis \| 1 C0004623 \| bacterial infections \| 1 C0032285 \| pneumonia \| 1 C0042164 \| uveitis \| 1 C0041296 \| tuberculosis \| 1 C0025295 \| pneumococcal meningitis \| 1 C0040053 \| thrombosis \| 1 C0042165 \| anterior uveitis \| 1 C0038220 \| status epilepticus \| 1 C0023890 \| cirrhosis \| 1 C0026764 \| myeloma \| 1
Curated Gene	(Waiting for update.)
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:4) 720 \| C4A \| infer 721 \| C4B \| infer 4179 \| CD46 \| infer 4153 \| MBL2 \| infer
Text Mined Gene	(Waiting for update.)
Locus	(Waiting for update.)

Disease ID	1632
Disease	meningitis, bacterial
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:31) HP:0001287 \| Meningitis \| 7 HP:0002315 \| Headaches \| 5 HP:0000388 \| Otitis media \| 2 HP:0000407 \| sensorineural hearing loss \| 2 HP:0100584 \| Endocarditis \| 2 HP:0002045 \| Abnormally low body temperature \| 2 HP:0000238 \| Nonsyndromal hydrocephalus \| 2 HP:0001297 \| Cerebral vascular events \| 2 HP:0001945 \| Fever \| 2 HP:0002170 \| Intracranial hemorrhage \| 1 HP:0012122 \| Anterior uveitis \| 1 HP:0000010 \| Frequent urinary tract infections \| 1 HP:0030151 \| Cholangitis \| 1 HP:0001250 \| Seizures \| 1 HP:0000365 \| Hearing impairment \| 1 HP:0002140 \| Ischemic stroke \| 1 HP:0001342 \| Intracerebral hemorrhage \| 1 HP:0002090 \| Pneumonia \| 1 HP:0001988 \| hypoglycemia, recurrent \| 1 HP:0012683 \| Pineal cyst \| 1 HP:0002181 \| Cerebral edema \| 1 HP:0000554 \| Uveitis \| 1 HP:0100806 \| Sepsis \| 1 HP:0002615 \| Low blood pressure \| 1 HP:0002133 \| Status epilepticus \| 1 HP:0004326 \| Cachexia \| 1 HP:0005305 \| Cerebral vein thrombosis \| 1 HP:0000969 \| Dropsy \| 1 HP:0001394 \| Hepatic cirrhosis \| 1 HP:0006702 \| Spontaneous coronary artery dissection \| 1 HP:0000371 \| Acute middle ear infection \| 1

Disease ID	1632
Disease	meningitis, bacterial
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:18) C0009450 \| infection \| 7 C0018681 \| headache \| 5 C1384666 \| hearing loss \| 5 C0032268 \| pneumocephalus \| 4 C0032285 \| pneumoniae \| 3 C0020255 \| hydrocephalus \| 2 C0021308 \| infarction \| 2 C0018784 \| sensorineural hearing loss \| 2 C0015967 \| fever \| 2 C1393529 \| vascular complications \| 2 C0007785 \| cerebral infarction \| 1 C0011053 \| deafness \| 1 C0016169 \| fistula \| 1 C0038220 \| status epilepticus \| 1 C0000833 \| abscess \| 1 C0016397 \| focal infections \| 1 C0036572 \| seizures \| 1 C0043046 \| wasting syndrome \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:9)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs1042714	22624056	127617	OR14L1P	umls:C0085437	BeFree	We identified a functional polymorphism in ADRB2 (rs1042714) to be associated with an increased risk for bacterial meningitis (Odds ratio [OR] 1.35, 95% confidence interval [CI] 1.04-1.76; p = 0.026).	0.000271442	2012	ADRB2	5	148826910	G	C,T
rs1047286	23068452	718	C3	umls:C0085437	BeFree	Rs1047286 (Pro314Leu) in complement component 3 was associated with reduced susceptibility to bacterial meningitis after correction for multiple testing: the protective Leu/Leu genotype was found in 5 of 435 patients (1%) compared to 15 of 302 controls (5%; odds ratio [OR] 4.50, 95% confidence interval [CI] 1.62-12.50, p = 0.0017).	0.000271442	2013	C3	19	6713251	G	A
rs1052133	26316174	4968	OGG1	umls:C0085437	BeFree	In recent papers published by our group, we described the associations between the single nucleotide polymorphisms (SNPs) AADAT +401C > T, APEX1 Asn148Glu, OGG1 Ser326Cys and PARP1 Val762Ala and BM.	0.000542884	2015	OGG1;CAMK1	3	9757089	C	G
rs1052133	26316174	142	PARP1	umls:C0085437	BeFree	In recent papers published by our group, we described the associations between the single nucleotide polymorphisms (SNPs) AADAT +401C > T, APEX1 Asn148Glu, OGG1 Ser326Cys and PARP1 Val762Ala and BM.	0.000271442	2015	OGG1;CAMK1	3	9757089	C	G
rs1052133	26316174	328	APEX1	umls:C0085437	BeFree	In recent papers published by our group, we described the associations between the single nucleotide polymorphisms (SNPs) AADAT +401C > T, APEX1 Asn148Glu, OGG1 Ser326Cys and PARP1 Val762Ala and BM.	0.000542884	2015	OGG1;CAMK1	3	9757089	C	G
rs1052133	21651918	4968	OGG1	umls:C0085437	BeFree	For the SNP OGG1 Ser326Cys, the genotype Cys/Cys was more frequent (P<0.05) in BM group.	0.000542884	2011	OGG1;CAMK1	3	9757089	C	G
rs1136410	26316174	142	PARP1	umls:C0085437	BeFree	In recent papers published by our group, we described the associations between the single nucleotide polymorphisms (SNPs) AADAT +401C > T, APEX1 Asn148Glu, OGG1 Ser326Cys and PARP1 Val762Ala and BM.	0.000271442	2015	PARP1	1	226367601	A	G
rs1136410	26316174	4968	OGG1	umls:C0085437	BeFree	In recent papers published by our group, we described the associations between the single nucleotide polymorphisms (SNPs) AADAT +401C > T, APEX1 Asn148Glu, OGG1 Ser326Cys and PARP1 Val762Ala and BM.	0.000542884	2015	PARP1	1	226367601	A	G
rs1136410	26316174	328	APEX1	umls:C0085437	BeFree	In recent papers published by our group, we described the associations between the single nucleotide polymorphisms (SNPs) AADAT +401C > T, APEX1 Asn148Glu, OGG1 Ser326Cys and PARP1 Val762Ala and BM.	0.000542884	2015	PARP1	1	226367601	A	G

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:14)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0085437	amikacin	D000583	37517-28-5	meningitis, bacterial	MESH:D016920	therapeutic	10223137
C0085437	ampicillin	D000667	69-53-4	meningitis, bacterial	MESH:D016920	therapeutic	1087098
C0085437	aztreonam	D001398	78110-38-0	meningitis, bacterial	MESH:D016920	therapeutic	2068463
C0085437	cefmetazole	D015311	56796-20-4	meningitis, bacterial	MESH:D016920	therapeutic	2232144
C0085437	cefotaxime	D002439	63527-52-6	meningitis, bacterial	MESH:D016920	therapeutic	3850855
C0085437	ceftazidime	D002442	78439-06-2	meningitis, bacterial	MESH:D016920	therapeutic	8122952
C0085437	chloramphenicol	D002701	56-75-7	meningitis, bacterial	MESH:D016920	therapeutic	16000513
C0085437	daptomycin	D017576	103060-53-3	meningitis, bacterial	MESH:D016920	therapeutic	21119097
C0085437	linezolid	D000069349	-	meningitis, bacterial	MESH:D016920	therapeutic	14766894
C0085437	moxifloxacin	C104727	-	meningitis, bacterial	MESH:D016920	therapeutic	12499193
C0085437	nafcillin	D009254	147-52-4	meningitis, bacterial	MESH:D016920	therapeutic	3852897
C0085437	piperacillin	D010878	61477-96-1	meningitis, bacterial	MESH:D016920	therapeutic	6391888
C0085437	rifampin	D012293	13292-46-1	meningitis, bacterial	MESH:D016920	therapeutic	16474940
C0085437	vancomycin	D014640	1404-90-6	meningitis, bacterial	MESH:D016920	therapeutic	10349306

FDA approved drug and dosage information(Total Drugs:6)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D016920	zyvox	linezolid	400MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D016920	zyvox	linezolid	200MG/100ML (2MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	No
MESH:D016920	zyvox	linezolid	100MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	Yes
MESH:D016920	zyvox	linezolid	400MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D016920	zyvox	linezolid	200MG/100ML (2MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	No
MESH:D016920	zyvox	linezolid	100MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	Yes

FDA labeling changes(Total Drugs:6)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D016920	12/19/2002	zyvox	linezolid	Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains	Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D016920	12/19/2002	zyvox	linezolid	Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains	Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D016920	12/19/2002	zyvox	linezolid	Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains	Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D016920	12/5/2005	zyvox	linezolid	Central nervous system infections	PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D016920	12/5/2005	zyvox	linezolid	Central nervous system infections	PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D016920	12/5/2005	zyvox	linezolid	Central nervous system infections	PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'

Web
Analytics